
HeartBeam reports higher ECG specificity in 132‑patient heart attack pilot
Sensitivity was slightly lower than standard ECGs; a U.S. pivotal study is planned for the first quarter of 2027.

The company confirms federal registrations but does not disclose how many dispensaries received them or identify their locations.

Sensitivity was slightly lower than standard ECGs; a U.S. pivotal study is planned for the first quarter of 2027.

The company allocated US$98.5M of new common-share proceeds to cash while funding preferred buybacks from its general-purpose cash account.
The generator kept its cash-flow and adjusted EBITDA forecasts while raising 2026 sustaining capital spending to C$350M to C$370M.
The Alaska result ended in high-grade mineralization and supports further testing of a possible second gold system at Flat.

Lumentum holders would own about 33 per cent of the combined company, with closing expected in the first half of 2028.

The New Jersey utility and nuclear owner kept its 2026 earnings outlook and expects to fund a US$24B to US$28B capital plan without new equity.

The Saskatchewan uranium explorer plans to test about four target areas, most beneath less than 50 metres of sandstone cover.

The developer is negotiating federal pilot-factory agreements while its first irradiated fuel samples undergo examination in Idaho.
The agency cited mouse toxicity and inadequate data for pediatric enrollment; the company is awaiting its full clinical hold letter.
PIF retains majority ownership as Aramco adds technology assets; HUMAIN targets three gigawatts of AI data-centre capacity by 2030.
A special-purpose subsidiary will issue the bonds, while Freedom guarantees obligations and project funding requires staged approvals.
Three investments reached final investment decision, including a Midwestern Gas Transmission expansion and an Indiana power-plant lateral.
The C$10M facility estimate excludes tenant-owned GPUs, while projected annual rent would be shared with its development partner.
The 10 billion yen investment runs through fiscal 2028 and primarily expands manufacturing for the latest LTO Ultrium 10 generation.
The final US$24.7M tranche supports five fuel-cell blocks, but the announcement omits net proceeds, repayment terms and delivery dates.
Gold, silver, uranium, lithium, copper and rare earths: the producers, the developers and the projects behind them.
View all
Macusani's measured and indicated material grades 213 parts per million uranium oxide, with an updated preliminary economic assessment underway.
Medical and pharmaceutical developments, psychedelics, and the research and safety questions around them.
View all
The agency set a May 1, 2027 action target for AMT-130 and is tentatively planning an advisory committee meeting.
Technology, computing, crypto and cannabis, and the listed companies moving in them.
View all
Barber Lake contracted rent now spans 20 years, while new convertible financing supports project equity and data halls open in phases.
Initial capacity of 1,440 MVA is scheduled for the end of 2029, while the land deal leaves cost and AI customer commitments undisclosed.
Uranium, lithium, oil and gas, hydrogen and the grid: the fuels and the companies behind them.
View all
The first new machine leaves Tennessee for final assembly in Ohio, ahead of a year-end manufacturing target.

The manufacturing agreement covers upper reactor coolant system components, with price, payment terms and delivery dates undisclosed.

PROPWR has about 510 MW under contract, while ProPetro targets 250 to 275 MW deployed by the end of 2026.
Licensed producers, retail, policy, and the psychedelics companies moving through the clinic.
View all
The brewer has cut its U.S. footprint to six facilities, while keeping fiscal 2027 adjusted earnings guidance unchanged.

Adjusted operating income turned positive, but an insurance benefit lifted cash generation and the IFRS net loss reached C$50.8 million.

Directors retain discretion over the ratio for common and exchangeable shares, with no effective date set in the voting disclosure.

The capsules are intended for three programs, including a Canadian Phase 3 PTSD trial of up to 100 people expected to begin in 2027.